Hypertension

>

Latest News

Baxdrostat for Resistant Hypertension Meets Primary Endpoints in BAX24 Phase 3 Clinical Trial
Baxdrostat for Resistant Hypertension Meets Primary Endpoints in BAX24 Phase 3 Clinical Trial

October 7th 2025

AstraZeneca will share the positive topline 24-hour BP monitoring data with global regulatory authorities and present findings at the 2025 AHA Scientific Sessions.

Salt Substitute Use Rare Among Adults With HTN: Daily Dose / image credit: ©New Africa/AdobeStock
Salt Substitute Use Rare Among Adults With HTN: Daily Dose

September 26th 2025

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension / image credit  ©Sundry Photos
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension

September 9th 2025

Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds
Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds

September 8th 2025

Fewer Than 1 in 4 Women Maintain Optimal CV Health in Menopause: Daily Dose / image credit: ©New Africa/AdobeStock
Fewer Than 1 in 4 Women Maintain Optimal CV Health in Menopause: Daily Dose

August 20th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.